SPRYARS Pharmaceuticals, Inc.vs its industry peers
A metric-by-metric comparison of ARS Pharmaceuticals, Inc. against SIC 2834 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| 기업 | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SPRY본 종목 | $543M#8 | — | 8.9x#13 | 6.4x#5 | -5.5%#5 | -2241.8%#14 | -212.9%#6 | -279.4%#14 | -134.4%#5 | — | — | — |
| CRMD | $592M#2 | 3.5x#2 | 1.4x#4 | 1.9x#1 | 617.0%#1 | 1009.4%#1 | 48.2%#1 | 37.3%#2 | — | — | — | — |
| ZVRA | $595M#1 | 5.0x#3 | 2.9x#7 | 5.6x#4 | 350.9%#2 | 178.9%#3 | -59.1%#4 | 40.4%#1 | — | — | — | — |
| GYRE | $586M#3 | — | 5.8x#11 | 5.0x#3 | 10.2%#3 | -44.8%#10 | 9.9%#2 | 9.8%#3 | 12.2%#1 | 4#1 | — | 7.7%#1 |
| NVCT | $571M#4 | — | 40.2x#14 | — | — | -39.2%#9 | — | -185.9%#13 | — | — | — | — |
| STTK | $559M#5 | — | 5.8x#12 | 559.0x#9 | -82.5%#8 | 35.3%#5 | -5150.8%#9 | -50.9%#11 | — | — | — | — |
| RLMD | $555M#6 | — | 2.5x#6 | 108182.7x#10 | -35.4%#7 | — | -1152275.3%#10 | 0.0%#5 | — | — | — | — |
| CBIO | $551M#7 | — | 3.4x#8 | 50.8x#7 | — | 306.4%#2 | -1407.5%#8 | 0.1%#4 | — | — | — | — |
| TENX | $536M#9 | — | 4.7x#10 | — | — | -198.9%#13 | — | -46.3%#10 | — | — | — | — |
| MPLT | $533M#10 | 1.3x#1 | 1.3x#2 | — | — | -107.7%#12 | — | -40.3%#9 | — | — | — | — |
| ARVN | $519M#11 | — | 1.3x#3 | 2.0x#2 | -0.3%#4 | 59.3%#4 | -45.1%#3 | -20.9%#6 | -39.5%#2 | — | — | — |
| NGNE | $517M#12 | — | 2.2x#5 | — | -100.0%#9 | -20.2%#8 | — | -38.0%#8 | — | — | — | — |
| BIOA | $479M#13 | — | 1.3x#1 | 53.2x#8 | — | -13.4%#7 | -1031.5%#7 | -21.3%#7 | -67.0%#3 | — | — | — |
| RZLT | $475M#15 | — | 4.1x#9 | — | — | -8.7%#6 | — | -63.7%#12 | -72.2%#4 | — | — | — |
| AQST | $475M#14 | — | — | 10.7x#6 | -22.6%#6 | -89.8%#11 | -159.5%#5 | — | — | — | — | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. 이 표는 생성 중 시간이 초과되어 그룹의 일부만 포함합니다. 순위는 표시된 행 내에서만 유효하며 곧 채워집니다. Table built 2026-08-04.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice